Monitor future 8-K filings for actual inducement grants under the 2026 Plan, which would signal new executive hires. The evergreen amendment modestly increases potential future dilution but is standard practice. No immediate trading catalyst.
Price Chart
Executive Summary
Camp4 Therapeutics held its 2026 Annual Meeting on June 10, 2026, where stockholders elected three Class II directors, ratified Ernst & Young as auditor, and approved an amendment to the 2024 Equity Incentive Plan to include pre-funded warrants in the evergreen share calculation. Separately, the Board adopted a new 2026 Inducement Plan reserving 500,000 shares for new-hire equity grants without stockholder approval under Nasdaq Rule 5635(c)(4). These are routine governance and compensation actions with no material financial impact.
Key Facts
- Stockholders approved Amendment No. 1 to the 2024 Equity Incentive Plan, adding outstanding pre-funded warrants to the evergreen share pool calculation (27,002,145 for, 10,023,588 against).
- Board adopted the 2026 Inducement Plan, reserving 500,000 shares of common stock for inducement grants to new employees under Nasdaq Rule 5635(c)(4).
- Three Class II directors elected: Steven Holtzman, Murray Stewart, and Richard Young, each to serve until the 2029 annual meeting.
- Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 passed with 39,998,507 votes for.
- No departures, officer changes, or material financial data reported.
Financial Impact
No financial impact. The 2026 Inducement Plan authorizes up to 500,000 shares for future new-hire grants, but no grants have been made yet.
Risk Factors
- Potential future dilution from up to 500,000 new shares under the Inducement Plan, though grants are at-the-money and tied to new hires.
- The 2024 Plan evergreen now includes pre-funded warrants in the share count, which could accelerate annual share pool growth if many warrants are exercised.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-042846 |
| Exhibit: exhibit103-camp4xinducemen.htm | 0001628280-26-042846 |
| Exhibit: exhibit101-amendmentno1to2.htm | 0001628280-26-042846 |
| Document: camp-20260610.htm | 0001628280-26-042846 |
| Document: 0001628280-26-042846-index-headers.html | 0001628280-26-042846 |
| Document: 0001628280-26-042846-index.html | 0001628280-26-042846 |
| Document: 0001628280-26-042846.txt | 0001628280-26-042846 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $4.34 $4.03 | ▼ −7.14% | ▼ −6.64% | $3.73 (−13.95%) |
Sep 2, 2026 29d ago | Insider Cluster | $4.49 $4.25 | ▼ −5.35% | ▼ −4.20% | $3.73 (−16.83%) |
Aug 21, 2026 6w ago | Insider Cluster | $4.48 $4.15 | ▲ +7.37% | ▲ +7.84% | $3.73 (+16.64%) |
Aug 13, 2026 7w ago | EFFECT | $4.50 $4.45 | ▼ −1.11% | ▲ +0.85% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Jul 27, 2026 9w ago | 8-K | $3.42 $3.45 | ▲ +0.88% | ▼ −0.20% | $3.73 (+9.20%) |
Jun 19, 2026 14w ago | Press Release | $4.20 $4.20 | · 0.00% | ▲ +2.07% | $3.73 (−11.08%) |
Jun 12, 2026 15w ago | 8-K | $3.96 $4.20 | ▲ +6.06% | ▲ +7.44% | $3.73 (−5.69%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.22 $4.14 | ▼ −1.90% | ▼ −2.33% | $3.73 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access